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中文摘要 
許多報告提及以干擾素(Interferon-alpha, IFN-α)治療慢性肝炎病患或癌症時
會誘發憂鬱症之副作用。然而，此機轉仍未清楚。血清胺運輸體(Serotonin 
transporter, 5-HTT)可使突觸間隙的血清胺(Serotonin, 5-HT)再回收至突觸前神
經元終端。目前所使用的抗憂鬱之治療藥，其作用方式與血清胺運輸體結合，
抑制血清胺再回收，增加血清胺含量，進而提高情緒。淋巴球被認為是反應神
經細胞功能較適合的標的，可用於研究精神相關疾病。先前研究指出若給予干
擾素可增加免疫細胞的血清胺運輸體 mRNA 和蛋白表現量，並促進血清胺再回
收。並且，實驗結果發現干擾素可促進血清胺運輸體的訊息調控與裂殖原活化
蛋白激酶(Mitogen-activated protein kinase, MAPK)相關。本實驗計畫分別給予
6-Bromo-indirubin-3'-oxime (Bio)和 Pyrrolidine dithiocarbamate (PDTC)阻斷肝醣
合成酶激酶 3 beta (Glycogen synthase kinase 3β, GSK3β) 和 NFκB 路徑， 結果
顯示 Bio 會抑制血清胺再回收能力，然而 PDTC 並不影響其再回收。進ㄧ步，
分別給予 Okadaic acid (OA)和 Wortamannin 阻斷蛋白質磷酸酶(Phosphatase 1 
and 2A, PP1/2A)和 PI3K/AKT，初步結果發現 OA 和 Wortamannin 皆會抑制血清
胺再回收能力。綜合上述結果指出干擾素促進血清胺再回收能力，其訊息調控
與 Phosphatase/AKT/GSK3β路徑有關。 
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英文摘要 
Clinical reports document that depression as a side effect is more prevalent in 
hepatic or cancer patients given interferon-alpha (IFN-α) therapy. The mechanisms, 
however, are poorly understood.  The serotonin transporter (5-HTT) is critical for 
terminating serotoninergic neurotransmission by taking up serotonin (5-HT) into 
presynaptic neurons; it is, therefore, an initial action site for selective 5-HTT reuptake 
inhibitors, which leads to an increase in 5-HT level and improves emotion.  
Lymphocytes have been used as neural probes in studying psychiatric disorders.  
Previous study has shown that treatment with IFNα increased 5-HTT mRNA 
expression, protein level, and 5-HT uptake in immune cells.  Furthermore, both 
IFN-α-induced 5-HT uptake and IFN-α-regulated transcription of 5-HTT correlated 
with mitogen-activated protein kinase (MAPK).  The aim of this project is to 
investigate the effects on IFN-α-induced 5-HT uptake after treatments with glycogen 
synthase kinase 3β (GSK3β) inhibitor 6-bromo-indirubin-3'-oxime (Bio) and 
NFkappaB inhibitor pyrrolidine dithiocarbamate (PDTC) in Jurkat-T cells.  Results 
showed that pre-incubation with Bio blocked IFN-α-induced 5-HT uptake, whereas 
PDTC did not alter this effect.  In addition, inhibitions of the phosphatase 1 and 2A 
by an inhibitor okadaic acid (OA) and phosphatidylinositol (3,4,5)-triphosphate 
kinase (PI3K)/AKT pathway by an inhibitor wortmannin induced a significant 
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reduction of IFN-α-induced 5-HT uptake.  Taken together, our results indicated that 
phosphatase/PI3K/AKT/GSK3 β pathways were related to IFN-α-induced 5-HT 
uptake. 
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Introduction 
Interferon (IFN)-α has been available for clinical use to treat chronic viral 
hepatitis and several malignancies. Although IFN-α therapy is frequently effective, 
several studies indicate that it causes neuropsychiatric disturbances, including 
depression (Fontana, 2000; Wichers and Maes, 2002; Capuron et al., 2004). More 
than 20% of patients receiving IFN-α therapy experience significant depressive 
symptoms over the first several months of treatment (Raison et al., 2005). Once 
symptoms have developed, patients can obtain relief by treatment with 
antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor (SSRI) 
(Musselman et al., 2001). 
The serotonin transporter (5-HTT) plays a critical role in terminating 
serotoninergic neurotransmission by the uptake of serotonin (5-HT) into presynaptic 
neurons; therefore, it is the initial target for an SSRI. It brings about an increase in the 
5-HT level and improves emotion (Stahl, 1998). In addition, 5-HTT was thought to be 
a potential substrate for the pathophysiology of suicide, and its levels correlated 
strongly with depressive symptoms (Purselle and Nemeroff, 2003). Further, 5-HTT 
has been detected in the plasma membrane of serotonergic neurons, platelets and 
human placenta (Ramamoorthy et al., 1993), as well as in lymphocytes (Faraj et al., 
1994; Marazziti et al., 1998), which have been used as neural probes for studying 
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psychiatric disorders, including depression. Moreover, T-cell activation and increased 
production of several proinflammatory cytokines are involved in depression 
(Gladkevich et al., 2004). 
IFN-α activates the antiviral and immunomodulating properties of MAPK and 
Janus kinase-STAT (David et al., 1995; Platanias, 2003). An upregulation of 5-HTT 
transcription in human placental choriocarcinoma (BeWo) cells (Morikawa et al., 
1998) and immune cells (Tsao et al., 2006) causes an IFN-α-induced increase in 5-HT 
uptake. Furthermore, MAPK is involved in IFN-α-induced 5-HT uptake and 
regulation of 5-HTT transcription (Tsao et al., 2008).  However, it is not clear 
whether the IFN-α causes this effect via glycogen synthase kinase 3beta (GSK3beta) 
and NFkappaB pathways.  Therefore, the aim of this project is to examine the effects 
on IFN-α-induced 5-HT uptake after treatments with GSK3beta or NFkappaB 
inhibitors in Jurkat-T cells to clarify the possible mechanisms of IFNα-induced 
depression. 
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Materials and Methods  
Cell lines 
The Jurkat T (ATCC TIB-152) cell line was a gift from B. C. Yang, PhD (Department 
of Microbiology and Immunology, National Cheng Kung University Medical College, 
Tainan, Taiwan). 
Chemicals 
IFN-2b was a gift from T. T. Chang, MD (Department of Internal Medicine, National 
Cheng Kung University Medical College, Tainan, Taiwan).  Bio, PDTC, and OA 
were purchased from Sigma-Aldrich (St. Louis, MO). Wortamannin was purchased 
from Tocris Cookson (Bristol, UK). 
Cell cultures 
Jurkat T cells were cultured in RPMI-1640 medium (Gibco BRL, Grand Island, NY, 
USA) containing 10% fetal calf serum and 0.1% gentamicin in 24-well plates (106 
cells/well).  The cell cultures were treated with different doses of ΙFN-α (25, 50 and 
100 U/ml), followed by Bio, PDTC, OA, or wortamannin.  Cells were harvested at 
various time ponts, and counted using a haemocytometer; the percent viability was 
determined by the trypan blue dye exclusion method. 
5-HT uptake 
Cells (5 × 106) from each treatment group were incubated with 0.01 mM 
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5-hydroxy[3H]tryptamine trifluoroacetate (Amersham Biosciences Corp., Piscataway, 
NJ) for 30 min at 25°C. Further, the cells were washed twice by centrifugation (1500 
rpm for 10 min) in PBS containing 50 µM fluoxetine and subsequently solubilized 
with 1% sodium dodecylsulphate (SDS). The radioactivity of the cell extracts was 
measured using a liquid scintillation counter (LS6500; Beckman Coulter, Inc, 
Fullerton, CA). 
Statistical analysis 
Student's t tests were performed to examine the 5-HT uptake as well as the differences 
between the drug-treated cells and the medium control cells.  Statistical significance 
was set at p < 0.05. 
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Results and Discussion 
Although IFN-α-induced 5-HT uptake correlated with MAPK, it is not clear 
whether the IFN-α causes this effect via GSK3β and NFκB pathways.  Therefore, 
we examined the effects of inhibitors for GSK3β and NFκB on IFN-α-induced 5-HT 
uptake.  Pre-incubating cells for 30 min with Bio blocked IFN-α-induced 5-HT 
uptake at 5 µM, whereas PDTC did not alter this effect at 10 µM (Fig. 1).  Recent 
study has been reported that decreases in GSK3β phosphorylation were directly 
proportional to levels of 5-HT synthesis and suggested that GSK3β play an important 
role in behavioral abnormalities induced by 5-HT deficiency (Beaulieu et al., 2008b).  
Several studies have been demonstrated that signaling molecules Akt and GSK3 
regulate behavior by dopamine and 5-HT (Beaulieu et al., 2008a).  In our study, 
pretreatment with the phosphatase 1 and 2A inhibitor OA at 50 nM and PI3K/AKT 
inhibitor wortmannin at 50 nM for 30 min caused significant reductions of 
IFN-α-induced 5-HT uptake (Fig. 2).  Taken together, our results indicated that 
phosphatase/PI3K/AKT/GSK3β pathways were related to IFN-α-induced 5-HT 
uptake. 
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Fig. 1 The effects of 6-bromo-indirubin-3'-oxime (Bio) and pyrrolidine 
dithiocarbamate (PDTC) inhibitors on IFN-α-induced 5-HT uptake.  The cells were 
treated for 30 min with different doses of Bio (5 µM) or PDTC (10 µM) prior to 
IFN-α treatment and harvested after 24 h. Uptake of 5-HT was subsequently 
determined using 0.1 mM 5-hydroxy-[3H]tryptamine trifluoroacetate. Data are 
presented after subtracting the nonspecific uptake and are expressed as the means 
(±SD) of the averages obtained in 3 experiments. *p < 0.05 as compared with the 
medium control cells or with the IFN-α-treated cells.  
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Fig. 2 The effects of okadaic acid (OA) and wortamannin inhibitors on 
IFN-α-induced 5-HT uptake.  The cells were treated for 30 min with different doses 
of OA (10 nM) or wortamannin (100 nM) prior to IFN-α treatment and harvested 
after 24 h. Uptake of 5-HT was subsequently determined using 0.1 mM 
5-hydroxy-[3H]tryptamine trifluoroacetate. Data are presented after subtracting the 
nonspecific uptake and are expressed as the means (±SD) of the averages obtained in 
3 experiments. *p < 0.05 as compared with the medium control cells or with the 
IFN-α-treated cells. 
